Cardiff Oncology (FRA:XE7C) Days Payable : 0.00 (As of Sep. 2024)

View and export this data going back to 1997. Start your Free Trial

What is Cardiff Oncology Days Payable?

Cardiff Oncology's average Accounts Payable for the three months ended in Sep. 2024 was €4.46 Mil. Cardiff Oncology's Cost of Goods Sold for the three months ended in Sep. 2024 was €0.00 Mil.

The historical rank and industry rank for Cardiff Oncology's Days Payable or its related term are showing as below:

During the past 13 years, Cardiff Oncology's highest Days Payable was 12592.50. The lowest was 197.11. And the median was 455.49.

FRA:XE7C's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 127.37
* Ranked among companies with meaningful Days Payable only.

Cardiff Oncology's Days Payable stayed the same from Sep. 2023 (0.00) to Sep. 2024 (0.00). stayed the same

Cardiff Oncology Days Payable Historical Data

The historical data trend for Cardiff Oncology's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cardiff Oncology Days Payable Chart

Cardiff Oncology Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Payable

Get a 7-Day Free Trial

Cardiff Oncology Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Days Payable	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Cardiff Oncology's Days Payable

For the Biotechnology subindustry, Cardiff Oncology's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cardiff Oncology's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cardiff Oncology's Days Payable distribution charts can be found below:

* The bar in red indicates where Cardiff Oncology's Days Payable falls into.

Cardiff Oncology Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Cardiff Oncology's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

	Days Payable (A: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2022 )	+	Accounts Payable (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (1.846	+	1.803)	/	2 )	/	0	*	365
=	1.8245					/	0	*	365
=	N/A

Cardiff Oncology's Days Payable for the quarter that ended in Sep. 2024 is calculated as:

	Days Payable (Q: Sep. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Jun. 2024 )	+	Accounts Payable (Q: Sep. 2024 ))	/	count )	/	Cost of Goods Sold (Q: Sep. 2024 )	*	Days in Period
=	( (4.745	+	4.183)	/	2 )	/	0	*	365 / 4
=	4.464					/	0	*	365 / 4
=	N/A

Cardiff Oncology Days Payable Related Terms

Thank you for viewing the detailed overview of Cardiff Oncology's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Cardiff Oncology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cardiff Oncology Inc (FRA:XE7C) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

CRDF:USA

Address

11055 Flintkote Avenue, San Diego, CA, USA, 92121

Website

https://www.cardiffoncology.com

Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").

Cardiff Oncology Headlines

No Headlines